** Shares of Integral Diagnostics IDX.AX rise 4.7% to A$2.25
** Citi upgrades healthcare facilities provider to 'Buy' from 'Neutral,' keeps PT unchanged at A$2.70
** Brokerage forecasts higher revenue and margins for IDX in FY26, buoyed by partial MRI de-regulation, potential lung cancer screening contract, and benefits from Capitol Health merger
** Stock rose 5.1% earlier in the session
** 13 analysts rate the stock "buy" or higher and 1 "hold"; their mean PT is A$3.13 – LSEG
** Including session's gains, stock trims YTD decline to 22.3%
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。